Google
Trusted Resources: News & Events
Latest announcements and gatherings
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)
GBT440 is First Potential Treatment for SCD To Be Accepted for PRIME.
PRIME Designation Allows for Frequent and Early Interactions with the Agency Aimed at Assisting Accelerated Evaluation and ApprovalF.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the European Medicines Agency (EMA) has determined that GBT440 for the treatment of sickle cell disease is eligible for its Priority Medicines (PRIME) program. The PRIME program is a new regulatory mechanism that provides for early and proactive EMA support to medicine developers to help patients benefit as early as possible from innovative new products that have demonstrated the potential to significantly address an unmet medical need.
+myBinderRelated Content
-
Foundation for Women & Girls with Blood DisordersIn 2010, the Foundation for Women & ...
-
Pediatric to Adult Transition in Sickle Cell Disease: Survey Results From Young Adult PatientsBackground/Aims: We surveyed sickle cel...
-
A survey of sickle cell patients transitioned to adult care from Texas children’s hematology center between Januar...An estimated 93-98% of sickle cell disea...
-
Spearheading change on World Sickle Cell DayThis year on World Sickle Cell Day, a ne...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
University of Pittsburgh School of MedicineThe University of Pittsburgh School of M...
-
The Rise and Fall of My Mental Health With Sickle CellWe all know that mental health and ment...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.